Market Research Logo

Global Migraine Market: Industry Analysis & Outlook (2018-2022)

Global Migraine Market: Industry Analysis & Outlook (2018-2022)

Migraine is a chronic neurologic disease characterized by severe recurrent headaches. It is one of the most common and most prevalent disabling neurological conditions, characterized by episodes often called migraine attacks. They are quite different from regular headaches which are non-migrainous. Migraineurs generally have a lower threshold to triggers that might cause neuronal hyperexcitability, including sleep disturbances, environmental or emotional challenges, alcohol exposure, diet, and hormonal cycles/changes, among others.

Migraine headache is typically throbbing, unilateral (one sided), and is aggravated by physical activity. It typically presents with additional symptoms in addition to headache pain, including nausea, and sensitivity to light and/or sound.

Depending on symptoms, migraine is broadly classified into two categories, Chronic and Episodic. Migraines can be treated with two types of drugs: pain-relieving and preventive. Pain-relieving medications are especially useful for people who have nausea or vomiting related to their migraine, and they work quickly. Preventive treatment is considered if migraine occurs frequently, typically more than one migraine per week, or if migraine symptoms are severe.

The global migraine market is expected to grow in future due to increasing female population, rising health expenditure, accelerating economic growth, increasing cigarette consumption, rising prevalence of migraine and unmet needs. Key trends of this market include development of migraine drugs and growing awareness regarding migraine and its treatments. However, there are some factors which can hinder the growth of migraine market which includes regulatory challenges, high cost, adverse effects of drugs, lack of proper diagnosis and increased preference of alternative therapies.

The report “Global Migraine Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, with focus majorly on the U.S. market. The report profiles the key players of the market including Amgen Inc., Eli Lilly and Company, Teva Pharmaceuticals & Alder Biopharmaceuticals.


1. Overview
1.1 Introduction
Table 1: Types of Migraine
1.2 Types
Table 2: Difference between Episodic and Chronic Migraine
1.3 Stages
Table 3: Stages of Migraine
1.4 Diagnosis
1.5 Treatment
2. Global Market Analysis
2.1 Global Migraine Market by Value
Table 4: Global Migraine Market by Value (2013-2017)
2.2 Global Migraine Market Forecast by Value
Table 5: Global Migraine Market Forecast by Value (2018-2022)
2.3 Global Migraine Market by Drug Type
Table 6: Global Migraine Market by Drug Type (2017)
2.4 Global Therapeutic Botulinum Toxin Market Forecast by Value
Table 7: Global Therapeutic Botulinum Toxin Market Forecast by Value (2017-2022)
2.5 Global Therapeutic Botulinum Toxin Market by Indication
Table 8: Global Therapeutic Botulinum Toxin Market by Indication (2017)
3. Regional Market
3.1 The U.S.
3.1.1 The U.S. Migraine Population Forecast
Table 9: The U.S. Migraine Population Forecast (2017-2022)
3.1.2 The U.S. Diagnosed & Treated Adult Migraine Population
Table 10: The U.S. Diagnosed and Treated Adult Migraine Population (2017-2022)
3.1.3 The U.S. Migraine Population with CV Risk Factors
Table 11: The U.S. Migraine Population with CV Risk Factors (2017-2022)
3.1.4 The U.S. Migraine Treatment by Specialty
Table 12: The U.S. Migraine Treatment by Specialty (2017)
3.1.5 The U.S. Migraine Treated Population by Drug Type
Table 13: The U.S. Migraine Treated Population by Drug Type (2017)
3.1.6 The U.S. Acute Migraine Prescription Volume
Table 14: The U.S. Acute Migraine Prescription Volume (2017-2022)
3.1.7 The U.S. Migraine Prophylaxis Market by Treatment
Table 15: The U.S. Migraine Prophylaxis Market by Treatment (2017)
3.2 The U.S. Migraine Drugs Revenue
3.2.1 The U.S. Botox Migraine Revenue and Treated Patients
Table 16: The U.S. Botox Migraine Revenue and Treated Patients (2017-2022)
3.2.2 The U.S. Cambia Drug Revenue
Table 17: The U.S. Cambia Drug Revenue (2017-2022)
3.2.3 The U.S. Lasmiditan Drug Revenue & Treated Patients
Table 18: The U.S. Lasmiditan Drug Revenue & Treated Patients (2018-2022)
3.2.4 The U.S. Alder Drug Revenue
Table 19: The U.S. Alder Drug Revenue (2019-2024)
3.2.5 The U.S. Erenumab Drug Revenue and Treated Patients
Table 20: The U.S. Erenumab Drug Revenue and Treated Patients (2018-2022)
3.2.6 The U.S. Galcanezumab Drug Revenue and Treated Patients
Table 21: The U.S. Galcanezumab Drug Revenue and Treated Patients (2019-2024)
3.2.7 The U.S. Fremanezumab Drug Revenue and Treated Patients
Table 22: The U.S. Fremanezumab Drug Revenue and Treated Patients (2019-2024)
3.3 Europe
3.3.1 Europe Total Migraine and Diagnosed Population
Table 23: Europe Total Migraine and Diagnosed Population (2017-2022)
3.4 Europe Migraine Drug Revenue
3.4.1 Europe Alder Drug Revenue
Table 24: Europe Alder Drug Revenue (2021-2026)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Growing Female Population
Table 25: Global Female Population (2013-2017)
4.1.2 Increasing Cigarette Consumption
Table 26: Global Cigarette Consumption (2014-2017)
4.1.3 Accelerating Economic Growth
Table 27: Global GDP Per Capita (2013-2017)
4.1.4 Increasing Healthcare Spending
Table 28: Global Healthcare Spending Per Capita (2013-2017)
4.1.5 Rising Prevalence of Migraine Cases
4.1.6 Unmet Needs
4.2 Key Trends & Development
4.2.1 Migraine Drugs under Development
Table 29: Migraine Drugs Under Development (2017)
4.2.2 Growing Awareness for Migraine
4.3 Challenges
4.3.1 Adverse Effects of Drugs
4.3.2 Lack of Proper Diagnosis
4.3.3 Increased Preference for Alternative Therapies
4.3.4 Regulatory Challenges
4.3.5 High Cost Associated
5. Competition
5.1 Global Market
5.1.1 Global Migraine Market- Revenue Comparison of Key Companies
Table 30: Global Migraine Market-Revenue Comparison of Key Companies (2017)
5.1.2 Global Migraine Market- Market Cap Comparison of Key Companies
Table 31: Global Migraine Market- Market Cap Comparison of Key Companies (2017)
5.1.3 Global Migraine Market- R&D Comparison of Key Companies
Table 32: Global Migraine Market- R&D Comparison of Key Companies (2017)
6. Company Profiles
6.1 Amgen Inc.
6.1.1 Business Overview
Table 33: Amgen Inc. Revenue by Geographic Region (2017)
6.1.2 Financial Overview
Table 34: Amgen Inc. Revenue and Net Income (2013-2017)
6.1.3 Business Strategies
Table 35: Amgen Inc. Research and Development Expenditure (2015-2017)
6.2 Eli Lilly and Company
6.2.1 Business Overview
Table 36: Eli Lilly and Company Revenue by Segments (2017)
6.2.2 Financial Overview
Table 37: Eli Lilly and Company Revenue and Net Income (2013-2017)
6.2.3 Business Strategies
Table 38: Eli Lilly and Company Research and Development Expenditure (2015-2017)
6.3 Teva Pharmaceuticals
6.3.1 Business Overview
Table 39: Teva Pharmaceuticals Revenue by Segments (2017)
6.3.2 Financial Overview
Table 40: Teva Pharmaceuticals Revenue and Net Income (2013-2017)
6.3.3 Business Strategies
6.4 Alder Biopharmaceuticals
6.4.1 Business Overview
Table 41: Alder Pharmaceuticals Pipeline Overview (2017)
6.4.2 Financial Overview
Table 42: Alder Biopharmaceuticals Revenue and Net Income (2013-2017)
6.4.3 Business Strategies
Table 43: Alder Biopharmaceuticals Research & Development Expenditure (2015-2017)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report